Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632137 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
A Phase 3 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
NCT01632137: Completed Phase 3 study, sponsored by Kubota Vision.
NCT01632137 is a Phase 3 study that has completed, run by Kubota Vision. The registered enrollment target is 564 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01632137, a Phase 3 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.
Interventions
- DRUG Rebamipide 2% ophthalmic suspension
- DRUG Placebo (vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2012-06 |
| Phase | Phase 3 |
What the finished NCT01632137 record still lists
NCT01632137 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Rebamipide 2% ophthalmic suspension is the first listed.
NCT01632137 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01632137 about?
NCT01632137 is a clinical study titled "Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome". The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.
What is the current status of trial NCT01632137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2012-06.
What interventions are being tested in trial NCT01632137?
The interventions under investigation include: Rebamipide 2% ophthalmic suspension (DRUG), Placebo (vehicle) (DRUG).
Who is sponsoring clinical trial NCT01632137?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01632137's enrollment target sits among peer trials
564 668th of 2000 higher than 1,333 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia